MIGLIETTA, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.971
AS - Asia 2.524
EU - Europa 1.807
AF - Africa 656
SA - Sud America 596
OC - Oceania 61
Continente sconosciuto - Info sul continente non disponibili 32
Totale 9.647
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.591
SG - Singapore 1.002
BR - Brasile 393
CN - Cina 374
IT - Italia 344
DE - Germania 313
HK - Hong Kong 273
FI - Finlandia 232
VN - Vietnam 161
PL - Polonia 82
GB - Regno Unito 71
IN - India 71
SE - Svezia 59
NL - Olanda 58
AR - Argentina 53
BJ - Benin 52
FR - Francia 51
AT - Austria 50
RU - Federazione Russa 50
TR - Turchia 42
CA - Canada 41
ID - Indonesia 40
MX - Messico 35
JP - Giappone 34
KR - Corea 32
CI - Costa d'Avorio 31
ES - Italia 31
IE - Irlanda 31
ZA - Sudafrica 30
PS - Palestinian Territory 29
IQ - Iraq 28
TN - Tunisia 28
CZ - Repubblica Ceca 27
JO - Giordania 26
EG - Egitto 24
MK - Macedonia 24
AE - Emirati Arabi Uniti 23
CH - Svizzera 23
CO - Colombia 23
GT - Guatemala 23
SA - Arabia Saudita 23
BS - Bahamas 22
LB - Libano 22
UY - Uruguay 22
EC - Ecuador 21
ET - Etiopia 21
HR - Croazia 21
IL - Israele 21
JM - Giamaica 21
CL - Cile 20
KZ - Kazakistan 20
MY - Malesia 20
NO - Norvegia 20
TT - Trinidad e Tobago 20
CD - Congo 19
MA - Marocco 19
AO - Angola 18
AZ - Azerbaigian 18
HN - Honduras 18
MD - Moldavia 18
MW - Malawi 18
NI - Nicaragua 18
NP - Nepal 18
PH - Filippine 18
RS - Serbia 18
SI - Slovenia 18
SK - Slovacchia (Repubblica Slovacca) 18
UA - Ucraina 18
ZW - Zimbabwe 18
BY - Bielorussia 17
CR - Costa Rica 17
CU - Cuba 17
CW - ???statistics.table.value.countryCode.CW??? 17
CY - Cipro 17
GM - Gambi 17
GN - Guinea 17
IS - Islanda 17
KE - Kenya 17
ME - Montenegro 17
ML - Mali 17
MN - Mongolia 17
PA - Panama 17
BA - Bosnia-Erzegovina 16
BB - Barbados 16
BG - Bulgaria 16
CV - Capo Verde 16
DK - Danimarca 16
DO - Repubblica Dominicana 16
IR - Iran 16
MG - Madagascar 16
RE - Reunion 16
VC - Saint Vincent e Grenadine 16
BO - Bolivia 15
EE - Estonia 15
LU - Lussemburgo 15
UZ - Uzbekistan 15
XK - ???statistics.table.value.countryCode.XK??? 15
ZM - Zambia 15
AL - Albania 14
AU - Australia 14
Totale 8.970
Salva come PNG Salva come JPEG
Città #
Singapore 597
Ashburn 564
Fairfield 379
Chandler 281
Hong Kong 239
Munich 230
Woodbridge 183
Helsinki 172
Houston 167
Cambridge 146
Seattle 143
San Jose 128
Ann Arbor 126
Beijing 125
Wilmington 117
Boardman 78
Los Angeles 77
Ho Chi Minh City 64
Padova 61
Santa Clara 52
Cotonou 49
Chicago 47
New York 46
Bytom 40
São Paulo 39
San Diego 37
Medford 35
Princeton 35
Warsaw 32
Hanoi 31
Abidjan 30
Turku 29
Des Moines 28
Buffalo 27
Hefei 27
Roxbury 27
London 26
Vienna 25
Amman 24
Dublin 24
Rome 22
Milan 21
Nassau 21
Salt Lake City 21
Tokyo 21
Nuremberg 20
Montreal 19
Dallas 18
Managua 18
Chennai 17
Conakry 17
Harare 17
Podgorica 17
Redondo Beach 17
Ulan Bator 17
Addis Ababa 16
Baku 16
Bamako 16
Bridgetown 16
Willemstad 16
Antananarivo 15
Brooklyn 15
Denver 15
Kingston 15
Kingstown 15
Kinshasa 15
Lusaka 15
Montevideo 15
Orem 15
Panama City 15
San José 15
Tashkent 15
Havana 14
Kampala 14
Lilongwe 14
Luanda 14
Nairobi 14
Reykjavik 14
Tampa 14
Villafranca Padovana 14
Andorra la Vella 13
Ankara 13
Baghdad 13
Council Bluffs 13
Dakar 13
Guatemala City 13
Jinan 13
Pristina 13
Pune 13
Seoul 13
Skopje 13
Vientiane 13
Amsterdam 12
Johannesburg 12
Jyväskylä 12
Kigali 12
Libreville 12
Minsk 12
Phoenix 12
Castries 11
Totale 5.493
Salva come PNG Salva come JPEG
Nome #
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 329
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 253
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 241
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 237
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 234
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 228
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer 218
Immune characterization of breast cancer metastases: Prognostic implications 217
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary 210
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 200
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives 198
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 198
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 197
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 193
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 188
Evolution of HER2-low expression from primary to recurrent breast cancer 183
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 175
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 173
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 170
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy 168
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 166
Breast cancer biological characterization - Evaluation of the prognostic and/or predictive role of clinical, pathological and molecular biomarkers to dissect breast cancer heterogeneity: focus on estrogen-low breast cancer 163
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 161
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases 160
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer 159
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 159
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 155
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 152
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 147
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 142
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 142
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 141
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 140
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 136
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives 134
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? 132
Abdominal Wall Reconstruction: Biomaterialsand Tissue Engineering Biomaterials 132
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 131
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study 128
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer 125
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival 124
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study 119
Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review 119
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases 115
Cardiac Safety of Adjuvant Trastuzumab and Paclitaxel for HER2+ early breast cancer patients published in Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM) 25-27 October, 2019 - Rome, Italy Abstracts 114
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 113
Olaparib for advanced breast cancer 104
Therapeutic strategies for the management of hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer: A review of the current literature 103
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer 101
ALLSTAR: inference of reliAble causaL ruLes between Somatic muTAtions and canceR phenotypes 100
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 100
Complicanze tromboemboliche in chirurgia plastica: osservazioni su 20000 procedure di chirurgia maggiore 97
Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients 96
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 96
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials 93
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group 92
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 91
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 89
An overview of immune checkpoint inhibitors in breast cancer 88
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 87
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications 86
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 78
How can we refine the prognostic stratification of triple-negative breast cancer? 77
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 71
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 68
HER2: a never ending story 67
Managing sexual health challenges in breast cancer survivors: A comprehensive review 61
Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications 52
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial 44
Impact of germline BRCA1/2 status on outcomes for patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a systematic review and meta-analysis 13
Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes 10
Temporal evolution of breast cancer brain metastases treatments and outcomes 9
Totale 9.792
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.563
article - articoli 28.692
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 313
Totale 58.568
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021362 0 0 0 0 0 0 45 49 72 107 48 41
2021/2022562 23 48 55 27 64 33 68 34 39 17 39 115
2022/2023556 93 70 35 68 54 59 20 28 88 3 30 8
2023/2024434 44 48 50 27 32 59 35 16 7 27 34 55
2024/20252.233 1 150 71 77 162 115 183 255 205 164 339 511
2025/20264.713 452 488 1.107 1.289 767 352 258 0 0 0 0 0
Totale 9.792